Application Note

Zydis® ODT - Improved Therapeutic Profile

Source: Catalent

Zydis® fast dissolve formulation for Zelapar® (Selegiline anti-Parkinson’s compound) had a positive impact on the patient compliance as compared to the Selegiline traditional tablets. It also demonstrates higher patient preference and adherence to prescriptions compared to traditional tablets for Selegiline in Parkinson’s disease and other therapeutic areas.